GO
Loading...

Medicine

More

  • *Novo expects to launch in first EU markets in H1 2015. *Shares in Novo rise 1.6 percent. Prospects for degludec- already on sale separately in Europe under the brand name Tresiba- and the new combination with Victoza are critical for Novo, which is the world's biggest insulin maker.

  • Europe backs new leukemia drugs from J&J and Gilead Friday, 25 Jul 2014 | 7:20 AM ET

    LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.

  • LONDON, July 25- A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

  • July 24- A pivotal trial of Keryx Biopharmaceuticals Inc's experimental drug Zerenex showed that it improved levels of serum phosphorus and iron in patients on kidney dialysis, according to results published on Thursday. The trial involved 441 patients, according to the Journal of the American Society of Nephrology, which published the results.

  • July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.

  • Deadly 'superbug' is spreading in US hospitals Thursday, 24 Jul 2014 | 2:03 PM ET

    CRE, one of the worst of the superbugs, is spreading in some hospitals, and there's worry that cases are under-reported.

  • More US girls now getting cervical cancer vaccine Thursday, 24 Jul 2014 | 1:08 PM ET

    NEW YORK— More teen girls are getting a controversial cervical cancer vaccine but the increase isn't much of a bump, the government reported Thursday. Last year's rise follows a couple of years when the girls' HPV vaccination rate was flat and health officials worried that it wouldn't budge. Anne Schuchat of the Centers for Disease Control and Prevention.

  • *Man collapsed at Lagos international airport. LAGOS, July 24- A Liberian man in his 40 s is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a mega-city of 21 million people, the Lagos State Health Ministry said on Thursday.

  • Man tested for Ebola in Africa's 'megacity' Lagos Thursday, 24 Jul 2014 | 11:57 AM ET

    A Liberian man is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a megacity of 21 million people.

  • LAGOS, July 24- A Liberian man in his 40 s is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a megacity of 21 million people, the Lagos State Health Ministry said on Thursday.

  • GSK asks European regulator to OK malaria shot Thursday, 24 Jul 2014 | 6:50 AM ET

    LONDON— Pharma giant GSK said Thursday it is submitting its malaria vaccine for regulatory approval to the European Medicines Agency. In a statement on Thursday, GSK said its vaccine is aimed only for use against the malaria parasite most prevalent in Africa.

  • LONDON, July 24- GlaxoSmithKline said on Thursday it is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.

  • BASEL, July 24- Swiss drugmaker Roche confirmed its full-year sales and profit targets on Thursday as growing momentum for its new breast cancer medicines and professional diagnostics products countered the effects of a strong Swiss franc.

  • July 23- Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, demonstrating that the furor over its price has not curtailed early use. Since its December launch, Sovaldi has been prescribed for more than 80,000 patients in the United States and Europe, the company said.

  • FDA approves new painkiller from OxyContin maker Wednesday, 23 Jul 2014 | 5:45 PM ET

    FDA regulators approved the drug for daily, round-the-clock pain that does not respond to other medications. The FDA notes that Targiniq can still be abused by simply swallowing the tablets, the most frequent method of painkiller abuse. The FDA has been under intense public pressure to combat the national epidemic of prescription opioid abuse.

  • Gilead beat Street estimates as Sovaldi sales soar Wednesday, 23 Jul 2014 | 4:05 PM ET
    Hepatitis-C medication Sovaldi is shown in this photo.

    Gilead Sciences delivered quarterly earnings and revenue that topped analysts' expectations on Wednesday.

  • July 23- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer. The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.

  • FDA approves Gilead Sciences drug for 3 cancers Wednesday, 23 Jul 2014 | 12:57 PM ET

    WASHINGTON— The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer. The FDA has approved three other drugs for the disease in the last year: Roche's Gazyva, Janssen Pharmaceutical's Imbruvica and GlaxoSmithKline's Arzerra.

  • U.S. FDA approves Gilead's blood cancer drug Zydelig Wednesday, 23 Jul 2014 | 12:05 PM ET

    July 23- The U.S. Food and Drug Administration has approved Gilead Inc's drug Zydelig to treat three types of blood cancer, the agency said on Wednesday. The FDA approved it for use in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.

  • CNBC's Meg Tirrell speaks to Dr. George Scangos, Biogen Idec CEO, about the company's Q2 earnings surge, drug pipeline, and America's tax code. Scangos says we need a corporate tax rate that is competitive with rest of the world and a territorial tax system.